| Medical Square | |
|
276 W Fullerton Ave Addison IL 60101-3767 | |
| (630) 543-5454 | |
| (630) 543-5471 |
| Full Name | Medical Square |
|---|---|
| Speciality | Internal Medicine |
| Location | 276 W Fullerton Ave, Addison, Illinois |
| Authorized Official Name and Position | Mohammed Saeed (PRESIDENT) |
| Authorized Official Contact | 6305435454 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Medical Square 276 W Fullerton Ave Addison IL 60101-3767 Ph: (630) 543-5454 | Medical Square 276 W Fullerton Ave Addison IL 60101-3767 Ph: (630) 543-5454 |
| NPI Number | 1023211224 |
|---|---|
| Provider Enumeration Date | 06/06/2007 |
| Last Update Date | 05/17/2012 |
| Medicare PECOS PAC ID | 3476511940 |
|---|---|
| Medicare Enrollment ID | O20041230000102 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023211224 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036067984 (Illinois) | Primary |
| Provider Name | Mohammed M Saeed |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1124188081 PECOS PAC ID: 9739147208 Enrollment ID: I20050103000042 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
| Provider Name | Richard V Dirkes |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1942289764 PECOS PAC ID: 8729023197 Enrollment ID: I20050627000183 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
| Provider Name | Neelima Sharma |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780832147 PECOS PAC ID: 2668509241 Enrollment ID: I20100430000275 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
| Provider Name | Yasmin Irfan Kagzi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1659525103 PECOS PAC ID: 0547423717 Enrollment ID: I20120525000417 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
| Provider Name | Saba N Saeed |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1285923524 PECOS PAC ID: 2860770054 Enrollment ID: I20161021001629 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
| Provider Name | Jyoti Kanda |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912544180 PECOS PAC ID: 3476964511 Enrollment ID: I20201123000552 |
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
News Archive
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services - from routine office visits to diagnostic tests and surgical procedures - could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.
Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
› Verified 8 days ago
Access Community Health Network Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1111 W Lake St, Addison, IL 60101 Phone: 773-257-6770 | |
Concentra Urgent Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 South Grace Street, Addison, IL 60101 Phone: 630-543-4040 Fax: 630-543-1050 | |
Ricardo Martinez, Md, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1201 W Army Trail Blvd, Addison, IL 60101 Phone: 630-458-9200 Fax: 630-458-8460 | |
Concentra Medical Centers Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 S Grace St, Addison, IL 60101 Phone: 630-543-4040 Fax: 630-543-1050 | |
Bozena Scigacz Medical Office S.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 28 W Lake St, Suite 2, Addison, IL 60101 Phone: 630-458-0688 Fax: 630-458-0698 | |
Primary Care Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 303 W Lake St, Suite 206, Addison, IL 60101 Phone: 630-543-4200 |